title: The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C.
authors.affiliation: Department of Pediatrics, Division of Gastroenterology and Nutrition, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. kschwarz@jhmi.edu
authors.forename: Kathleen B
authors.initials: KB
authors.lastname: Schwarz
authors.forename: Regino P
authors.initials: RP
authors.lastname: Gonzalez-Peralta
authors.forename: Karen F
authors.initials: KF
authors.lastname: Murray
authors.forename: Jean P
authors.initials: JP
authors.lastname: Molleston
authors.forename: Barbara A
authors.initials: BA
authors.lastname: Haber
authors.forename: Maureen M
authors.initials: MM
authors.lastname: Jonas
authors.forename: Philip
authors.initials: P
authors.lastname: Rosenthal
authors.forename: Parvathi
authors.initials: P
authors.lastname: Mohan
authors.forename: William F
authors.initials: WF
authors.lastname: Balistreri
authors.forename: Michael R
authors.initials: MR
authors.lastname: Narkewicz
authors.forename: Lesley
authors.initials: L
authors.lastname: Smith
authors.forename: Steven J
authors.initials: SJ
authors.lastname: Lobritto
authors.forename: Stephen
authors.initials: S
authors.lastname: Rossi
authors.forename: Alexandra
authors.initials: A
authors.lastname: Valsamakis
authors.forename: Zachary
authors.initials: Z
authors.lastname: Goodman
authors.forename: Patricia R
authors.initials: PR
authors.lastname: Robuck
authors.forename: Bruce A
authors.initials: BA
authors.lastname: Barton
mesh_terms: D000293:Adolescent; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004359:Drug Therapy, Combination; D005260:Female; D016174:Hepacivirus / Q000187:drug effects; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D009503:Neutropenia / Q000139:chemically induced; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use*; D012367:RNA, Viral / Q000032:analysis / Q000187:drug effects; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a